睿知中国医院研究地图
候选清单

正在招募肺癌未注明分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)

ClinicalTrials.gov 上登记的一项肺癌开放试验,由中南大学湘雅二医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方中南大学湘雅二医院Second Xiangya Hospital长沙医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05477979,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically confirmed diagnosis of NSCLC;

    入选标准第 2 条

  3. Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;

    入选标准第 3 条

    Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition;

    排除标准第 10 条

    Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition;

    排除标准第 24 条

    Pathologically stage conformed as early stage of IA-IIIA

    排除标准第 37 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

    入选标准第 4 条

    Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

    排除标准第 11 条

  5. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) gene and/or ROS proto-oncogene 1 (ROS1) fusion-positive;

    排除标准第 1 条

    Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) gene and/or ROS proto-oncogene 1 (ROS1) fusion-positive;

    排除标准第 29 条

  6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ;

    入选标准第 6 条

    Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ;

    排除标准第 13 条

    At least one measurable lesion can be evaluated according to the RECIST 1.1 standard;

    排除标准第 25 条

  7. Combined with other malignant tumors in the past 3 years;

    排除标准第 2 条

    Pathologically diagnosed as small cell lung cancer;

    排除标准第 9 条

    Combined with other malignant tumors in the past 3 years;

    排除标准第 16 条

    Pathologically diagnosed as non-small cell lung cancer;

    排除标准第 23 条

    Combined with other malignant tumors in the past 3 years;

    排除标准第 30 条

    Pathologically diagnosed as non-small-cell lung cancer;

    排除标准第 36 条

    Combined with other malignant tumors in the past 3 years;

    排除标准第 42 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05477979,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥ 18 years;
  2. Histologically confirmed diagnosis of NSCLC;
  3. Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
  5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );
  6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ;
  7. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy;
  8. Informed and agreed to participate in the study;

排除标准:Exclusion Criteria:

  1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) gene and/or ROS proto-oncogene 1 (ROS1) fusion-positive;
  2. Combined with other malignant tumors in the past 3 years;
  3. Concurrent acute or chronic psychiatric disorders;
  4. Current receiving anti-depressive or anti-anxiety therapy;
  5. Previous treatment with other clinical drug trials;
  6. Patients with symptomatic brain metastasis;
  7. Can't cooperate with psychological scale assessment;
  8. Age ≥ 18 years;
  9. Pathologically diagnosed as small cell lung cancer;
  10. Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition;
  11. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
  12. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );
  13. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ;
  14. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy;
  15. Informed and agreed to participate in the study;
  16. Combined with other malignant tumors in the past 3 years;
  17. Concurrent acute or chronic psychiatric disorders;
  18. Current receiving anti-depressive or anti-anxiety therapy;
  19. Previous treatment with other clinical drug trials;
  20. Patients with symptomatic brain metastasis;
  21. Can't cooperate with psychological scale assessment;
  22. Age ≥18 years ;
  23. Pathologically diagnosed as non-small cell lung cancer;
  24. Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition;
  25. At least one measurable lesion can be evaluated according to the RECIST 1.1 standard;
  26. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );
  27. Receiving PD-1/PD-L1 inhibitors combined with chemotherapy as neoadjuvant therapy.
  28. Cardiopulmonary function can withstand surgery; 7. Informed and agreed to participate in the study;
  29. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) gene and/or ROS proto-oncogene 1 (ROS1) fusion-positive;
  30. Combined with other malignant tumors in the past 3 years;
  31. Concurrent acute or chronic psychiatric disorders;
  32. Current receiving anti-depressive or anti-anxiety therapy;
  33. Previous treatment with other clinical drug trials;
  34. Can't cooperate with psychological scale assessment;
  35. Age ≥18 years;
  36. Pathologically diagnosed as non-small-cell lung cancer;
  37. Pathologically stage conformed as early stage of IA-IIIA
  38. Available for tumor tissue samples;
  39. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );
  40. Receiving radical surgery;
  41. Informed and agreed to participate in the study;
  42. Combined with other malignant tumors in the past 3 years;
  43. Concurrent acute or chronic psychiatric disorders;
  44. Current receiving anti-depressive or anti-anxiety therapy;
  45. Previous treatment with other clinical drug trials;
  46. Can't cooperate with psychological scale assessment;

引自 ClinicalTrials.gov, NCT05477979, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05477979,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05477979